|Day Low/High||38.02 / 38.91|
|52 Wk Low/High||31.32 / 50.90|
"It's not a joke, it's a rope, Tuco. Now I want you to get up there and put your head in that noose." -- Blondie in "The Good, the Bad and the Ugly." I did very little today, save adding to my bank/financial shorts. I moved back to Market Neutral. ...
The drugmaker's shares were hammered Friday on news that the industry is slashing prices.
With a $31 billion debt load, the drugmaker has to show it has the firepower needed to fend off creditors.
Here are some high-profile and widely-held stocks whose charts should concern the bullish cabal: Netflix Starbucks Disney Tesla Coca-Cola Prudential Ford Valeant Perrigo Dollar Tree Macy's Nike Note: These stocks represent a broad swath of secto...
Stocks climbed, though worries over how soon the Federal Reserve might hike interest rates kept markets wary.
The activist fund says Perrigo's promises over the past year have been "woefully unfulfilled."
Falling crude oil prices continued to weigh on markets Monday.
U.S. stocks edged back from records highs set last week as resurfacing supply worries took a chunk out of crude prices.
Ralph Lauren shares surge on earnings beat amid lethargic market action.
Perrigo might have been in more of a decline than the market realized when it turned down Mylan's $26 billion offer for the company last year, says Jim Cramer.
I'm not inclined to make market calls, but the action on my screen is pushing me to a defensive stance.
The stock's tumbling to near a 52-week low, but charts suggest caution.
Analysts say Tuesday's earnings beat could spell trouble in terms of coping with its $31 billion worth of debt.
A lost leader in Celgene and a Perrigo rumor have put a scare in the charts.
Papa is set to meet with Walgreens management in hopes of ironing out "speed bumps."
Problems with mesh products and high leverage might scare away a potential buyer.
I was out of the office yesterday, but my take on the session is: "Up, Down, Up, Flat." It was a mixed day in terms of economic data, with potholes everywhere. (You'd have to be blind not to see them.) It was all about retail yet again, and it sure ...
The drugmaker's quest to rebrand itself as a patient-first company is foundering over renewed controversy over drug pricing.
Despite an earnings beat and upbeat outlook, its stock has suffered with other drug makers.
Did I mention that the market has no memory from day to day? It was a busy short-side day for me today. Disney (DIS) -- why the mouse is no longing roaring. On management B.S. Macy's (M). Sears (SHLD) is the elephant in the room and a possible ...
It reports tomorrow, but where will the company ultimately fall this quarter?
"Papa's in the swing. He ain't too hip about that new breed babe. He ain't no drag. Papa's got a brand new bag." -- James Brown, Papa's Got a Brand New Bag Jim "El Capitan" Cramer clearly outlined the key risks facing Valeant Pharmaceuticals (VRX) t...
Jim Cramer thinks Allergan CEO Brent Saunders has put together a world class company.
New Valeant CEO and former Perrigo CEO Joseph Papa will be joining TheStreet's Jim Cramer on "Mad Money" tonight.
Perrigo could have an oversold bounce at any time as bears turn aggressive, but nothing right now indicates a price bottom.
I noted in my previous missive that my ursine friend Jim Chanos spoke out on CNBC's Fast Money Halftime show today in favor of shorting the Chinese stock market. Well, he also just expressed skepticism on Valeant Pharmaceuticals (VRX) -- another vie...
"Valeant, of course, was a sewer ... [and its directors deserve] all the opprobrium they are getting." -- Charlie Munger, vice chairman of Berkshire Hathaway (BRK.A, BRK.B), at this weekend's annual Berkshire shareholder meeting Pershing Square's Bi...